Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pralatrexate - Acrotech Biopharma

Next Previous
Drug Profile

Pralatrexate - Acrotech Biopharma

Alternative Names: 10-Propargyl-10-deazaaminopterin; Difolta; FOLOTYN; Folotyn; PDX

Latest Information Update: 22 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center; Southern Research Institute; SRI International
  • Developer Acrotech Biopharma; Columbia University; Mundipharma International; Rafa Laboratories; Servier
  • Class Antineoplastics; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma; Peripheral T-cell lymphoma; Follicular lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Bladder cancer; Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase I/II Lymphoma; Multiple myeloma
  • No development reported B-cell lymphoma; Bladder cancer; Breast cancer; Cutaneous T-cell lymphoma; Hodgkin's disease; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 16 Feb 2024 Launched for Peripheral T-cell lymphoma (Second-line therapy or greater) in China (IV)
  • 27 Nov 2023 Phase-III clinical trials in Peripheral T-cell lymphoma (Combination therapy, First-line therapy) in USA (IV)
  • 12 Oct 2023 Acrotech Biopharma plans a phase III CRESCENDO trial for Peripheral T-cell lymphoma (Combination therapy) in USA in October 2023 (Parenteral) (NCT06072131)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top